Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUMMB: Pembrolizumab and Radiotherapy in Advanced Bladder Cancer
NCT02560636Phase 1Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2016
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in bladder cancer (5 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Maximum Tolerated Dose at 36 months and Rates of Toxicity. Started Jun 2016; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02560636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560636.